Xiang Yunsheng

Xiang Yunsheng

Auto-generated profile, based on publicly available information

Xiang Yunsheng

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 102401, People’s Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Degenerative Neurological and Neuromuscular Disease
Verified
Journal Article
Open access
PDF file
TDTunan Ding
Tunan Ding
JCJunlei Chen
Junlei Chen
YXYunsheng Xiang
Yunsheng Xiang
XZXiao-Jie Zhou
Xiao-Jie Zhou
HZHongbo Zheng
Hongbo Zheng
YFYin Fu
Yin Fu
Objective: This study aimed to identify novel therapeutic targets for Alzheimer’s disease (AD) by investigating the role of the intestinal flora (IF) via the gut-brain axis, and to predict a potential natural compound for AD treatment and elucidate its underlying mechanism. Methods: Following a primary analytical axis, we first employed Mendelian randomization (MR) to infer causal relationships between gut microbiota and AD. To pinpoint molecular targets, we integrated Summary-data-based MR (SMR) with single-cell and spatial transcriptomics. Subsequently, network pharmacology and molecular docking were used to identify stigmasterol as a candidate compound targeting the causal pathway. Finally, the neuroprotective effects and the STIM1/Orai1-mediated mechanism were experimentally validated in vitro using Aβ1-42 exposed SH-SY5Y cells. Results: MR-based causal inference identified Desulfovibrio as a risk factor for AD, while Slackia and the Lachnospiraceae NK4A136 group were protective factors. Seven key AD-related genes were identified by combining MR results with databases, which were highly druggable. SMR analysis and multi-omics integration pinpointed STIM1-mediated calcium signaling as the core causal pathway. Following the identification of stigmasterol via network pharmacology and molecular docking, in vitro experimental validation confirmed that stigmasterol significantly inhibited Aβ1-42 induced neuronal apoptosis and calcium overload by specifically modulating the STIM1/Orai1 pathway and the Bcl-2/Bax ratio. Conclusion: This study decodes the gut-brain axis by establishing the specific causal pathway. We demonstrate that Stigmasterol exerts neuroprotective effects by inhibiting apoptosis through a IF-associated mechanism involving the STIM1/Orai1 pathway, provideing novel insights into AD pathogenesis and offering a promising therapeutic strategy based on natural compounds.

1 March 2026 in Gut Medicine
Verified
Journal Article
Open access
XYXiang Yunsheng
Xiang Yunsheng
YYYan Yumeng
Yan Yumeng
Sepsis‐related liver injury (SRLI) involves multiple interrelated pathological processes, including excessive inflammation, oxidative imbalance, mitochondrial dysfunction, dysregulated autophagy, and microcirculatory impairment. Increasing evidence indicates that traditional Chinese medicine (TCM)–based interventions, particularly Chinese medicine injections and Chinese medicine monomeric small molecules, modulate multiple interconnected signaling nodes implicated in SRLI. This review systematically synthesizes current experimental and clinical evidence regarding the protective effects of representative TCM injections and Chinese medicine monomeric small molecules in SRLI models. Across LPS‐ and CLP‐based paradigms, these interventions consistently converge on key regulatory modules such as NF‐κB–mediated inflammatory signaling, Nrf2/HO‐1–dependent antioxidant responses, mitochondrial homeostasis, autophagy‐related pathways, and inflammasome activation. Emerging findings suggest that their therapeutic effects are not confined to isolated linear pathways but involve coordinated regulation and functional cross talk among redox balance, inflammatory transcription, metabolic adaptation, and cell‐death programs. Although encouraging mechanistic and preliminary clinical data have been reported, most current evidence is still derived from basic studies or small‐scale clinical investigations. Future research should strengthen pharmacokinetic evaluation, mechanistic validation at the network level, standardized quality control, and high‐quality randomized clinical trials to clarify the translational potential of TCM‐based strategies in SRLI.